With More Cash from Wisconsin, GenTel Will Roll Out Pre-Spotted Diagnostic Array in 06 | GenomeWeb

GenTel BioSurfaces took another step towards commercializing a line of pre-spotted antibody arrays late last month by securing a $250,000 loan from the state of Wisconsin.

Made available through the state's Venture Capital Fund, which offers low-interest loans to local companies, the extra cash is part of a larger push by the Madison, Wisc.-based firm to bring a diagnostic array to market by early 2006, according to GenTel's CEO Alex Vodenlich.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.